Regeneron to buy 23andMe for $256M in court-supervised sale

Sundry Photography/iStock Editorial via Getty Images

Regeneron Pharmaceuticals (NASDAQ:REGN) will buy substantially all assets of genetic testing firm 23andMe (OTC:MEHCQ) for a purchase price of $256M.

23andMe filed for bankruptcy protection in March this year. Regeneron emerged as the successful bidder in the bankruptcy auction for 23andMe